Combined secondary outcomes, propensity score-matched as-treated analyses
| Tocilizumab (n=16 074) | TNFi (n=33 109) | HR (95% CI) | Rate difference† | |||||
| Events | Person-years | IR (95% CI) | Events | Person-years | IR* (95% CI) | |||
| Serious bacterial infection | 522 | 13 221 | 3.95 (3.60 to 4.29) | 865 | 29 114 | 2.97 (2.77 to 3.17) | 1.19 (1.07 to 1.33) | 0.98 (0.59, 1.37) |
| Septicaemia/bacteraemia | 230 | 13 341 | 1.72 (1.50 to 1.95) | 442 | 29 320 | 1.51 (1.37 to 1.65) | 1.04 (0.88 to 1.22) | 0.21 (−0.05, 0.47) |
| Pneumonia/upper respiratory tract infection | 186 | 13 346 | 1.39 (1.19 to 1.59) | 394 | 29 300 | 1.34 (1.21 to 1.48) | 0.92 (0.77 to 1.10) | 0.05 (−0.19, 0.29) |
| Pyelonephritis/UTI | 65 | 13 393 | 0.49 (0.37 to 0.60) | 160 | 29 407 | 0.54 (0.46 to 0.63) | 0.77 (0.58 to 1.04) | −0.05 (−0.20, 0.10) |
| Opportunistic infection | 18 | 13 417 | 0.13 (0.07 to 0.20) | 37 | 29 473 | 0.13 (0.09 to 0.17) | 0.99 (0.55 to 1.79) | 0 .00 (−0.07, 0.07) |
| Skin and soft tissue infection | 37 | 13 414 | 0.28 (0.19 to 0.36) | 34 | 29 473 | 0.12 (0.08 to 0.15) | 2.38 (1.47 to 3.86) | 0.16 (0.06, 0.26) |
| Herpes zoster | 15 | 13 415 | 0.11 (0.06 to 0.17) | 33 | 29 466 | 0.11 (0.07 to 0.15) | 0.90 (0.48 to 1.69) | 0.00 (−0.07, 0.07) |
| Diverticulitis | 70 | 13 403 | 0.52 (0.40 to 0.64) | 61 | 29 437 | 0.21 (0.16 to 0.26) | 2.34 (1.64 to 3.34) | 0.31 (0.18, 0.44) |
| Tuberculosis | NR | 13 421 | 0.00 (0.00 to 0.00) | NR | 29 483 | 0.00 (0.00 to 0.01) | NA | NA |
| Viral hepatitis | NR | 13 421 | 0.00 (0.00 to 0.00) | NR | 29 482 | 0.00 (0.00 to 0.01) | NA | NA |
*Incidence rate (IR) is per 100 person-years.
†Rate difference per 100 patients (tocilizumab-TNFi).
NA, not available; NR, not reported; TNFi, tumour necrosis factor inhibitors; UTI, urinary tract infection.